Agree BL, the science is strong, compelling some t
Post# of 148190
(Total Views: 274)
Posted On: 09/20/2019 7:09:39 AM
Re: Bored Lawyer #8397
Agree BL, the science is strong, compelling some to stick around even if they worry about other items.
I will say one item NP has done well, brought in a great science team, best of the best. These people wouldn't be here if they didn't believe in the product. Also, Samsung looked at their data, said you have the data, we will make the product for you, help with the BLA, you can pay us later, after you get approval. They would not have done that if they were not convinced. And we have the FDA saying they admittedly want drug approval. And we have published research with many different teams testing pro 140 in resistance, effectiveness, etc, showing the great results. It is all there. It will get done soon.
They main person in most ccr5 trials, starting on early 2000s, has been Jacob Lalezari , who is their main point person and attends FDA meetings.
https://www.nejm.org/doi/full/10.1056/nejmoa0803152
https://www.ncbi.nlm.nih.gov/pubmed/16135896
Thomson is another, she lists herself as research support for cydy in some documents, https://aidsinfo.nih.gov/contentfiles/lvguide...centGL.pdf
Pestell, Sacha and Lindser they brought in as science advisors March 2018, some like Pestell had been working with them earlier, 2017or 2016
https://www.cytodyn.com/newsroom/press-releas...ce-pro-140
Daniel Lindner, MD, Ph.D., is Director of Animal Tumor Core of the Taussig Cancer Institute at the Cleveland Clinic. He received a BS in biology from MIT, medical degree from Georgetown University, Ph.D. in microbiology from the Medical College of Wisconsin.
Jonah Sacha, Ph.D., is associate professor at OHSU and has appointments in the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center. He received his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison and B.S. in Biology from the University of Missouri-Columbia.
Also John Marshall
Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer
John Marshall, MD, is a global leader in the research and development of drugs for colon cancer and other GI cancers. He is the principal investigator of over 150 clinical trials at both the local and national levels. Dr. Marshall is the associate director for clinical care of the Lombardi Comprehensive Cancer Center and the chief of the Division of Hematology-Oncology at MedStar Georgetown University Hospital.
and
Massimo Cristofanilli, the leading expert in CTC technology, PI with many breast cancer trails, Professor of Medicine in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine.
I will say one item NP has done well, brought in a great science team, best of the best. These people wouldn't be here if they didn't believe in the product. Also, Samsung looked at their data, said you have the data, we will make the product for you, help with the BLA, you can pay us later, after you get approval. They would not have done that if they were not convinced. And we have the FDA saying they admittedly want drug approval. And we have published research with many different teams testing pro 140 in resistance, effectiveness, etc, showing the great results. It is all there. It will get done soon.
They main person in most ccr5 trials, starting on early 2000s, has been Jacob Lalezari , who is their main point person and attends FDA meetings.
https://www.nejm.org/doi/full/10.1056/nejmoa0803152
https://www.ncbi.nlm.nih.gov/pubmed/16135896
Thomson is another, she lists herself as research support for cydy in some documents, https://aidsinfo.nih.gov/contentfiles/lvguide...centGL.pdf
Pestell, Sacha and Lindser they brought in as science advisors March 2018, some like Pestell had been working with them earlier, 2017or 2016
https://www.cytodyn.com/newsroom/press-releas...ce-pro-140
Daniel Lindner, MD, Ph.D., is Director of Animal Tumor Core of the Taussig Cancer Institute at the Cleveland Clinic. He received a BS in biology from MIT, medical degree from Georgetown University, Ph.D. in microbiology from the Medical College of Wisconsin.
Jonah Sacha, Ph.D., is associate professor at OHSU and has appointments in the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center. He received his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison and B.S. in Biology from the University of Missouri-Columbia.
Also John Marshall
Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer
John Marshall, MD, is a global leader in the research and development of drugs for colon cancer and other GI cancers. He is the principal investigator of over 150 clinical trials at both the local and national levels. Dr. Marshall is the associate director for clinical care of the Lombardi Comprehensive Cancer Center and the chief of the Division of Hematology-Oncology at MedStar Georgetown University Hospital.
and
Massimo Cristofanilli, the leading expert in CTC technology, PI with many breast cancer trails, Professor of Medicine in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼